Cochran John 4

What Happened John Cochran, a director of Aquestive Therapeutics (AQST), was granted a derivative award on 2026-06-10 covering 50,500 shares at an acquisition price of $0.00 (i.e., an option/award grant with no cash paid at grant). The reported grant has a $0 immediate cash value on the Form 4; the underlying shares vest 100% on June 10, 2027, subject to Cochran’s continued service through that date. This is an award (not a purchase or sale).

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12.
• Instrument: Derivative award (options) for 50,500 shares; acquisition price reported $0.00.
• Vesting: 100% of the underlying shares vest on June 10, 2027, subject to continuous service (footnote).
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: Form 4 was filed two days after the transaction date (no late-filing flag indicated).

Context

• This was a grant of a derivative award (options) rather than an open-market purchase or sale; the grant does not represent an immediate cash outlay or sale of shares.
• Because the award vests in one year and is subject to continued service, it provides future equity incentive rather than immediate ownership.